Neutrophil-Related Genes Predict Prognosis and Contribute to Immunosuppression in Acute Myeloid Leukemia [0.03%]
中性粒细胞相关基因可预测急性髓系白血病预后并参与免疫抑制作用
Di Zhang,Yongjian Li,Tingting Liu et al.
Di Zhang et al.
Introduction: Acute myeloid leukemia (AML) prognosis remains challenging due to limited biomarkers integrating tumor microenvironment (TME) dynamics. Neutrophils, key mediators of immune regulation, exhibit dual roles in ...
Optimizing Timing and Preparation for Allogeneic Hematopoietic Stem Cell Transplantation in Higher-Risk Myelodysplastic Syndromes [0.03%]
高危骨髓增生异常综合征异基因造血干细胞移植的时机和术前准备优化研究
Liangquan Geng,Erling Chen,Yanping Ji et al.
Liangquan Geng et al.
Introduction: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curative treatment for higher-risk myelodysplastic syndromes (MDS), but optimal timing and donor selection remain controversial. ...
Clinical Characteristics, Prognostic Risk Factors, and Primary Treatment for Elderly Patients with Primary Central Nervous System Lymphoma: A Seer Database-Based Research [0.03%]
基于SEER数据库的原发中枢神经系统淋巴瘤老年患者临床特征、预后风险因素及初始治疗研究
Mengyao Zhang,Runyu Yang,Yue Du et al.
Mengyao Zhang et al.
Background: Primary central nervous system lymphoma (PCNSL) is a highly aggressive extranodal non-Hodgkin's lymphoma. Moreover, there is currently no specific prognostic model for elderly PCNSL patients. ...
Advancing AML Treatment: Evidence-Based Regimens and Guideline Updates for Targeted Treatments in R/R AML [Podcast] [0.03%]
基于证据的方案和指南更新在复发或难治性AML中的应用[ podcasts ]
Amer M Zeidan,Eunice Wang
Amer M Zeidan
Acute myeloid leukemia (AML) is a heterogeneous malignancy characterized by diverse genetic mutations, including IDH1 and IDH2, which are present in approximately 15-20% of cases. Recent clinical practice guidelines, including the 2025 NCCN...
Deep Dive into Targeted Therapies: Understanding IDH1-Mutant AML Treatments [Podcast] [0.03%]
深入了解靶向疗法：理解IDH1突变型急性髓系白血病的治疗[podcast]
Amer M Zeidan,Courtney DiNardo
Amer M Zeidan
This podcast episode reviews recent advances in the treatment of IDH1-mutant acute myeloid leukemia (AML), focusing on the mechanisms, efficacy, and safety profiles of approved IDH1 inhibitors. The purpose is to present expert insights and ...
Advancing Leukemia Diagnosis and Treatment: WHO-Supported Laboratory Innovations in Africa- A Narrative Review [0.03%]
世界卫生组织支持的实验室创新在非洲推动白血病诊断和治疗的发展——叙述性综述
Emmanuel Ifeanyi Obeagu
Emmanuel Ifeanyi Obeagu
Leukemia remains a major health challenge in Africa, where limited access to advanced diagnostic technologies often leads to delayed diagnosis and suboptimal treatment outcomes. This review explores the role of WHO-supported laboratory inno...
Unveiling the Mysteries of Molecular Testing in AML: A Guide for Oncologists [Podcast] [0.03%]
揭开AML分子检测的神秘面纱—— oncologists podcast听众指南
Amer M Zeidan,Sanam Loghavi
Amer M Zeidan
In the first episode of the AML Expert Series, titled Unveiling the Mysteries of Molecular Testing in AML: A Guide for Oncologists, experts from Yale Cancer Center and MD Anderson Cancer Center describe the evolving landscape of molecular d...
A Monocyte-Driven Prognostic Model for Multiple Myeloma: Multi-Omics and Machine Learning Insights [0.03%]
多发性骨髓瘤单核细胞驱动的预后模型：多组学和机器学习见解
Linzhi Xie,Meng Gao,Shiming Tan et al.
Linzhi Xie et al.
Background: Multiple myeloma (MM) is a haematological malignancy, driven by complex interactions between tumor and immune cells. Nevertheless, the overall pattern of immune cells and MM pathogenesis within the bone marrow...
An Updated Indirect Comparison of Elranatamab Versus a Real-World External Control Arm in Triple-Class Refractory Multiple Myeloma [0.03%]
关于Elranatamab versus三重治疗难治性多发性骨髓瘤的间接比较的更新研究
Luciano J Costa,Thomas W LeBlanc,Hans Tesch et al.
Luciano J Costa et al.
Purpose: Elranatamab is a BCMAxCD3 bispecific antibody approved for the treatment of relapsed/refractory multiple myeloma (RRMM). The registrational Phase 2 MagnetisMM-3 (NCT04649359) trial was single-armed; the aim of th...
Ahmad Al-Jarrad,Samhar Samer Alouch,Yogesh Chawla et al.
Ahmad Al-Jarrad et al.
T-cell engagers (TCEs) are engineered to bind both the CD3 subunit on T-cells and specific antigens on tumor cells, triggering T-cell activation and tumor cell lysis. TCEs targeting B-cell maturation antigen (BCMA) and G-protein-coupled rec...